Lars Dreesmann

Boehringer Ingelheim AB develops, produces, markets and sells pharmaceutical products. The firm also provides research, development, manufacturing and marketing services in the therapeutic field of human and veterinary medicine. The company was founded in 1967 is headquartered in Stockholm, Germany.

Boehringer Ingelheim RCV GmbH & Co. KG develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments. The company was founded in 1885 by Albert Boehringer and is headquartered in Vienna, Austria.

C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany.

Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT.

NGN Capital LLC (NGN Capital) is a venture capital firm founded in 2003 by Kenneth S. Abramowitz and William J. Gedale. The firm is headquartered in New York.

Founded in 2016, Boehringer Ingelheim Corporate Center GmbH is a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The company is based in Ingelheim am Rhein, Germany and specializes in leasing real estate properties.

Sudpack Medica designs and manufactures medical plastic packaging solutions. The private company is based in Baar, Switzerland.

Part of Bayer AG, Bayer (Schweiz) AG is a Swiss company that develops new molecules to improve the health of humans, animals and plants with products and solutions. The company is based in Zurich, Switzerland.

Part of Uhlmann Pac-Systeme GmbH & Co. KG, Uhlmann Pac-Systeme Verwaltungsgesellschaft mbH supplies pharmaceutical packaging systems. The company is based in Laupheim, Germany. The CEO of the German company is Norbert Gruber.

Part of Profunda Verwaltungs GmbH & Co. KG, the German company provides asset management services. The company is based in Ingelheim am Rhein, Germany. The CEOs of the company are Hubertus von Baumbach, Christoph Gauger.

Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co., KG is a company that operates research-based pharmaceutical companies and serves. Boehringer Ingelheim Pharma GmbH & Co., KG is based in Ingelheim, Germany. The German company was founded in 1885 by Albert Boehringer. The CEO is Hubertus von Baumbach.

Cobepa SA is an investment holding Belgian company. The company is based in Brussels, Belgium. The company was founded in 1957. The CEO is Jean-Marie Laurent Josi.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Carl-Zeiss-Stiftung is a company-linked foundation. The firm manages the companies Carl Zeiss AG and SCHOTT AG, which specialize in optics and optoelectronics, as well as specialty glass and glass-ceramics. It also promotes the sciences, engineering, and mathematics at universities through dividends from the Foundation firms. The company was founded by Ernst Abbe on May 19, 1889 and is headquartered in Stuttgart, Germany.

Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom.

Part of Ferring Ventures, FinVector Oy is a Finnish biopharmaceutical company that specializes in manufacturing viral-based gene therapy products. The company is based in Kuopio, Finland, and has extensive experience in cgmp manufacturing. FinVector employs hundreds of highly qualified professionals from over 40 different countries and works on cutting-edge biopharmaceuticals. It has invested in building state-of-the-art gmp facilities for viral vector platforms. The company was founded in 1993 by Seppo Ylä-Herttuala, and the CEO is Giuseppe Carloni.